VectivBio AG Employee Directory

Biotechnology ResearchBasel-Stadt, Switzerland51-200 Employees

VectivBio AG is a Basel, Switzerland-based clinical-stage biotechnology company focused on rare diseases and targeting conditions with clearly defined biology through transformative therapeutics. It originated in 2019 as a spinout from Therachon, a company whose achondroplasia program was acquired by Pfizer. The firm’s lead program addresses Short Bowel Syndrome, and its collaboration strategy includes an exclusive license with Asahi Kasei Pharma to develop apraglutide for multiple indications, including SBS with intestinal failure and steroid-refractory acute graft-versus-host disease, with potential future Japan indications. In 2023, VectivBio announced a merger with Ironwood Pharmaceuticals. The company employs 51 to 200 people and maintains a website at vectivbio.com.

Sign up for free to view info

Company overview Email format